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INTRODUCTION
Wiskott-Aldrich syndrome (WAS) (Online Mendelian
Inheritance in Man [OMIM] 301000) is an X-linked reces-
sive disorder characterized by thrombocytopenia, eczema,
and immunodeficiency. Clinical symptoms include petechi-
ae, bloody diarrhea, inability to generate antibodies against
polysaccharide antigens, and in some cases, autoimmune
manifestations. Affected boys often die because of malignant
tumors, particularly lymphoma (1, 2). Treatments for WAS
include antimicrobial therapy for infections, intravenous
immune globulin, splenectomy for thrombocytopenia, and
allogeneic bone marrow transplantation (3-5).
The gene responsible for WAS was isolated, and designat-
ed the WAS gene (6). The gene is composed of 12 exons span-
ning approximately 9 kilobases. The encoded protein is a
502 amino-acid long intracellular protein, which is broadly
expressed in hematopoietic cells (7). The WAS gene was found
to be mutated, not only in classic WAS patients, but also in
patients with X-linked thrombocytopenia (XLT), which is a
clinically mild allelic variant (8, 9). Recent reports have ex-
panded the WAS mutation phenotype to include intermit-
tent XLT, X-linked neutropenia with or without myelodys-
plasia, or WAS/XLT in females with heterozygous mutations
(10, 11).
Many WAS gene mutations have been reported in patients
with WAS. However, little is known about Korean WAS pa-
tients in terms of their molecular genetic diagnosis. In this
report, we describe a Korean family with WAS, which was
diagnosed as having exon 2 mutation, based on the WAS
gene mutation analysis. This is the first identified case of a
hotspot mutation in exon 2 of WAS in Korea. 
MATERIALS AND METHODS
Subjects
A one-day-old male neonate was admitted to the hospital
because of jaundice and petechiae on the body. He was born
after 37 weeks gestation, by Cesarean section due to breech
presentation and had a birth weight of 2,800 g. Laboratory
data showed a hemoglobin of 16.8 g/dL, a white blood cell
count of 17,050/ L, a platelet count of 39,000/ L, and a high
reticulocyte count (9.1%), but Coombs’ tests were negative.
The level of serum bilirubin (total/direct) was 7.3/0.4 mg/dL,
and the result of the liver function test was unremarkable.
Also, immunoglobulin (Ig) M titers to TORCH were nega-
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A Familial Case of Wiskott-Aldrich Syndrome with a Hotspot Mutation
in Exon 2 of the WAS Gene
The Wiskott-Aldrich syndrome (WAS) is a severe X-linked disorder characterized
classically by thrombocytopenia, immunodeficiency, and eczema. The phenotype
observed in this syndrome is caused by mutation in the WAS gene. Peripheral
blood DNAs were isolated from an 18-month-old boy with WAS and his mother,
maternal uncle, and maternal grandmother. Genetic analysis for the detection of a
mutation of WAS gene was performed by polymerase chain reaction-single strand
conformational polymorphism analysis (PCR-SSCP) and direct sequencing of the
PCR product. In PCR-SSCP, the patient and his maternal uncle had an abnormal
shift band, which was not found in normal controls, and his mother and maternal
grandmother showed heterozygous bands. In direct sequencing analysis, the patient
with WAS had CGC→CAC point mutation in exon 2 that resulted in an amino acid
change in codon 86 (Arg86His). The present study identified a gene mutation respon-
sible for WAS at a mutation hotspot of the WAS gene in a Korean family.
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tive. Serum Ig measurements at day 1 revealed an elevated Ig
A level (28.8 mg/dL; normal range, 1.3-3.6) (Ig G: 1,216.8,
Ig M<23.8, Ig D<1.5, and Ig E<18.0). The results of periph-
eral blood smear were unremarkable, except for a markedly
decreased number of platelets. A bone marrow aspiration
smear showed slight erythroid and megakaryocytic hypopla-
sia. Karyotyping analyses of both the patient and his moth-
er were normal. A review of family history revealed his mater-
nal uncle was clinically diagnosed as having WAS at five
years of age. The patient was treated with platelet transfu-
sion, and petechiae on the body disappeared immediately.
However, the patient’s thrombocytopenia persisted. When
the patient was 18 months old, genetic counseling was pro-
vided at his mother’s request. 
Mutation analysis
Genomic DNA was isolated from peripheral blood leuko-
cytes by using the Wizard Genomic DNA purification kit,
according to the manufacturer’s instructions (Promega, Ma-
dison, WI, U.S.A.). In order to examine mutations on the
WAS gene, polymerase chain reaction-single strand confor-
mational polymorphism (PCR-SSCP) was performed for all
12 coding regions of the WAS gene by using the primer sets
as listed in Table 1. The PCR was performed with a thermal
cycler (model 2400, Applied Biosystems, Foster City, CA,
U.S.A.) as follows: 32 cycles of 1 min at 94℃ for denatura-
tion, 1 min at 55-60℃ for annealing depending on the
primers, and 1 min at 72℃ for extension. Final extension
was performed at 72℃ for 10 min. The PCR products were
electrophoresed on an agarose gel and stained with ethidium
bromide to confirm the size of the bands. The PCR products
were also denatured in formamide loading buffer and elec-
trophoresed through 8% and 10% polyacrylamide gels. Sil-
ver stain was performed to develop bands (12). To determine
the sequences of the DNA samples showing mutant bands,
direct sequencing was performed on the ABI Prism 3100
Genetic Analyser (Applied Biosystems).
RESULTS
PCR and subsequent SSCP analysis in exon 2 of the WAS
gene identified an aberrantly migrating band in the patient’s
mother, and in his maternal grandmother, compared to two
wild type bands in the controls. The patient and his mater-
nal uncle showed two bands, one of which was a lower wild
single strand band and the other, an abnormal shifted band
(Fig. 1). In the direct sequencing analysis of the PCR prod-
ucts for SSCP, the missense mutation was observed in the
patient and his maternal uncle. This showed G-to-A transi-
tion at complementary nucleotide 257 (c.257G>A) (Fig. 2C),
resulting in substitution of His for Arg at codon 86 (Arg86-
His) (CGC→CAC). The patient’s mother and his maternal
grandmother were heterozygous for the mutation at codon
86 (Fig. 2B).
DISCUSSION
Mutations of the WAS gene result in 3 distinct pheno-
types: the classic WAS triad of thrombocytopenia with small
platelets, recurrent infections as a result of immunodeficien-
cy, and eczema (1); the milder XLT variant, characterized
Exon
Primer sequences
(5′ →3′ )
Product size
(bp)
1 Forward CAT TGC GGA AGT TCC TCT TC 220
Reverse CAG GAG ATC CCC AGC TCA C
2 Forward TAC CCC TGA CCA GAC TCC AC 237
Reverse GGT TTG GGG GTT GAG AAC T
3 Forward CTC CCA CCC TAC ACC TCT CC  164
Reverse TTC CCA TCT CCT CTC CAC AC
4 Forward CTC ACT TGG GGT GTG GAG AG 219
Reverse ACC TCT GCC CAA CTT CCT TT
5 Forward AAG TCC CCT CTC ATG GTC CT 195
Reverse AGC CCT CCT CTT CTC TCT GG
6 Forward GTG GCA GGG CTG TGA TAA CT 223
Reverse GCT CGT CCA TCC ACA TAC CT
7 Forward AGC CAA CCA CCC TAT TTT CC  246
Reverse CTC TGC CCC CAG GAA TCT
8 Forward AAG GAA GGG CAG TGA GGA TT 158
Reverse TCT CAG CAG TGG TCT TTG GA
9 Forward CCT GGC CTT TTT CCT CCT  208
Reverse AGA AGG GAG CGT ATG GAA GC
10-1 Forward TGT GTT ATA CCC CCT CCA CAG  237
Reverse GGG GCA GTG GTC CAG AAC
10-2 Forward CCA CCC CCT CCA GCT ACT 250
Reverse CCA TCC TGC CTG TCC TCA C
11 Forward TAA GCC CTC TGT GCT GAT CC  187
Reverse CTG GGC GCC AGG TTT GAG
12 Forward AAC CTC CCA GGG CAT CTT AT  244
Reverse CAG GCA GGG ATA ACA GCA TT
Table 1. PCR primers for amplification of the WAS gene
Fig. 1. Single-strand conformational polymorphism patterns for
exon 2 of the WAS gene. Patient’s mother and his maternal grand-
mother showed an extra band above upper normal single strand
band in lane 5 and 7. In lane 6 and 8, patient and maternal uncle
exhibited two bands, a normal lower single strand band and a
mobility shift band. In lane 1-4, normal subjects showed two sin-
gle strand bands.
12 34 5 6 7 8
PCR, polymerase chain reaction; WAS, Wiskott-Aldrich syndrome.1000 S.-K. Park, C.-S. Kim, D.-K. Song, et al.
predominantly by thromobocytopenia with small platelets
(8, 9); and finally, congenital neutropenia without the clini-
cal findings characteristic for WAS/XLT (10, 11).
As shown in WASPbase (13), a database of mutations, a
total of 441 cases consisted of missense mutations in 179
cases (40.6%), deletions in 92 cases (20.9%), nonsense muta-
tions in 64 cases (14.5%), splicing defects in 64 cases (14.5
%), and insertions in 42 cases (9.5%). The exon distribu-
tion of over 5% frequency of mutation was located in exon
2 (27.0%), exon 10 (16.1%), exon 1 (13.8%), exon 4 (9.8
%), exon 3 (7.5%), and exon 7 (6.4%). Notably, the frequen-
cy at codon 86 in exon 2 was 33.6% (40/119 cases). It is well
known that the codon 86 of the WAS gene is the most com-
mon missense mutation site responsible for WAS/XLT (10,
13). To our knowledge, this is the first report on the hotspot
missense mutation in exon 2 of WAS gene in Korea.
There are several reports on WAS mutations in Korean
families (Table 2). As shown in Table 2, the predominant
mutations were nonsense mutations and missense mutations
(14-18). Only one small deletion was reported in exon 10
(15). In this report, we found a missense mutation in exon
2. In Korean patients’ reports, including our results, muta-
tions in exon 1, 2, 3, 7, 8, and 10 have been involved in WAS.
Therefore, although it is necessary to accumulate mutation
data from a large number of patients with WAS, the distri-
bution of mutations may be highly diverse in Korean patients,
as had been observed in other reports (9, 10, 13).
A correlation between clinical phenotype and genotype
was reported independently by several investigators (19-21),
but was not observed by all (22, 23). Imai et al. demonstrat-
ed that all WAS patients with missense mutations showed
WASP-positive expression; in contrast, patients with non-
sense mutations, large deletions, small deletions, and small
insertions were WASP-negative expression. Patients with
splicing mutations were either WASP-negative or WASP-
positive. Lack of WASP expression was associated with severe
clinical symptoms and poor prognosis (24). Jin et al. report-
ed 5 mutational hotspots in the WAS gene from 227 WAS/
XLT families with a total of 262 affected members. They
also noted that the missense mutation at codon 86 was ob-
served most frequently and associated with mild symptoms
(25). Two previous reports (24, 25) showed that there is a
strong possibility of establishing an association between geno-
type and phenotype. In spite of advances in the clinical treat-
ment of WAS patients, WAS remains a life-threatening con-
dition, resulting in a poor quality of life and a bad long-term
prognosis, especially for those who lack an HLA-matched
sibling. The discovery of the WAS gene, and the identifica-
tion of the molecular basis of WAS, have made it possible to
provide genetic counseling for at-risk families. Therefore,
this report on the hotspot missense mutation in exon 2 of
WAS gene, will help this patient’s parent and his maternal
uncle to understand WAS and plan both genetic counseling
and family regulation.
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